专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0189548A3 PHARMACEUTICAL USE OF FIBULIN-1 审中-公开
标题翻译： FIBULIN-1的药物使用
公开(公告)号：WO0189548A3
公开(公告)日：2003-01-23
申请号：PCT/US0116791
申请日：2001-05-24
申请人： SCHERING AG , UNIV NORTH CAROLINA , HESS-STUMP HOLGER , HAENDLER BERNARD , LESSEY BRUCE , CHWALISZ KRISTOF
发明人： HESS-STUMP HOLGER , HAENDLER BERNARD , LESSEY BRUCE , CHWALISZ KRISTOF
IPC分类号： A61K48/00 , A61K35/12 , A61K35/76 , A61K38/00 , A61K38/17 , A61K38/39 , A61K39/395 , A61P13/00 , A61P15/00 , A61P15/08 , C07K14/78 , C12Q1/68 , G01N33/68
CPC分类号： C07K14/78 , A61K35/12 , A61K38/39 , A61K48/00
摘要： This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
摘要翻译：本发明涉及在女性避孕中的纤维蛋白-1多肽和纤维蛋白-1核酸的药物用途以及子宫内膜异位症的治疗和诊断。

2. 发明专利

AU6490001A Pharmaceutical use of fibulin-1 未知
公开(公告)号：AU6490001A
公开(公告)日：2001-12-03
申请号：AU6490001
申请日：2001-05-24
申请人： SCHERING AG , UNIV NORTH CAROLINA
发明人： HESS-STUMP HOLGER , HAENDLER BERNARD , LESSEY BRUCE , CHWALISZ KRISTOF
IPC分类号： A61K48/00 , A61K35/12 , A61K35/76 , A61K38/00 , A61K38/17 , A61K38/39 , A61K39/395 , A61P13/00 , A61P15/00 , A61P15/08 , C07K14/78

3. 发明专利

JP2003000273A New human androgen receptor mutant 有权
标题翻译：新人类受体受体突变体
公开(公告)号：JP2003000273A
公开(公告)日：2003-01-07
申请号：JP2001366404
申请日：2001-11-30
申请人： Schering Ag , シエーリングアクチエンゲゼルシャフト
发明人： AHRENS-FATH ISABELLE , HAENDLER BERNARD
IPC分类号： G01N33/50 , A61K31/711 , A61K45/00 , A61K48/00 , A61P15/16 , A61P35/00 , C07K7/06 , C07K14/72 , C07K16/28 , C12N5/10 , C12N15/09 , C12N15/12 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566 , G01N33/574 , G01N33/74
CPC分类号： G01N33/57434 , A61K48/00 , C07K14/721 , C07K16/2869 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/743 , G01N2800/52
摘要： PROBLEM TO BE SOLVED: To obtain a new tumor medicine based on an androgen receptor. SOLUTION: A new androgen receptor mutant named AR42 and AR32.
摘要翻译：要解决的问题：获得一种基于雄激素受体的新型肿瘤药物。解决方案：一种名为AR42和AR32的新型雄激素受体突变体。

4. 发明专利

JP2004043468A Endocrine gland derived vascular endothelial growth factor / prokinecitine 2-recipient antagonist 有权
标题翻译：内啡肽衍生的血管内皮生长因子/ PROKINECITINE 2受体拮抗剂
公开(公告)号：JP2004043468A
公开(公告)日：2004-02-12
申请号：JP2003182936
申请日：2003-06-26
申请人： Schering Ag , シエーリングアクチエンゲゼルシャフト
发明人： HAENDLER BERNARD , HESS-STUMPP HOLGER , SCHMIDT ANJA
IPC分类号： G01N33/53 , A61K31/7088 , A61K38/00 , A61K38/18 , A61K39/395 , A61K45/00 , A61K48/00 , A61P7/04 , A61P15/00 , A61P35/00 , A61P43/00 , C12N15/09 , C12N15/12 , C12N15/18 , C12Q1/68 , G01N33/566
CPC分类号： A61K31/7088 , A61K38/1808 , G01N2333/475 , G01N2500/04 , G01N2500/10
摘要： PROBLEM TO BE SOLVED: To provide a new means for therapy and diagnosis of endometriosis and endometroid carcinoma.
SOLUTION: EG-VEGF polypeptide, prokinecitine 2 polypeptide, effector of EG-VEGF nucleic acid and prokinecitine 2 nucleic acid or the corresponding recipient is pharmaceutically used for therapy and diagnosis of endometriosis and endometroid carcinoma and therapy of unusual bleeding. Further, in order to diagnose the receptiveness, an amount of the EG-VEGF, prokinecitine 2 or EG-VEGF/prokinecitine 2 recipient is measured.
COPYRIGHT: (C)2004,JPO
摘要翻译：要解决的问题：为子宫内膜异位症和子宫内膜癌的治疗和诊断提供新的手段。解决方案：EG-VEGF多肽，原肌宁酸2多肽，EG-VEGF核酸和原肌宁酸2核酸的效应物或相应的受体是药学上用于子宫内膜异位和子宫内膜癌的治疗和诊断以及异常出血的治疗。此外，为了诊断接受性，测定EG-VEGF，原肌宁酸2或EG-VEGF /原肌宁酸2受体的量。版权所有（C）2004，JPO

5. 发明专利

JP2002330771A HUMAN PEM AS TARGET FOR BIRTH CONTROL AND FOR TREATING ALZHEIMER'S DISEASE 失效
公开(公告)号：JP2002330771A
公开(公告)日：2002-11-19
申请号：JP2001164593
申请日：2001-05-31
申请人： SCHERING AG
发明人： WEISS BERTRAM , GESERICK CHRISTOPH , HAENDLER BERNARD
IPC分类号： G01N33/50 , A61K31/7088 , A61K35/76 , A61K38/00 , A61K45/00 , A61K48/00 , A61P15/08 , A61P15/16 , A61P25/28 , C07K14/47 , C12N5/10 , C12N5/22 , C12N15/09 , C12N15/12 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566
摘要： PROBLEM TO BE SOLVED: To provide human polymorphic epithelial mucin(PEM) that plays an important role in maturity of sperm and Alzheimer's disease and the nucleic acid encoding the human PEM. SOLUTION: The invention comprises the use of PEM as a target of male birth control and in the treatment for male sterilization and Alzheimaer's disease. This invention additionally comprises a method of selecting PEM antagonist and a method of producing a linked molecule that specifically detects PEM and provides the genes that are controlled by the PEM gene.

6. 发明专利

JP2002325600A METHOD FOR DIAGNOSING HETEROTOPIC ENDOMETRIO IN VITRO 审中-公开
公开(公告)号：JP2002325600A
公开(公告)日：2002-11-12
申请号：JP2001292209
申请日：2001-09-25
申请人： SCHERING AG
发明人： HESS-STUMPP HOLGER , HAENDLER BERNARD , KRAETZSCHMAR JOERN , KREFT BERTHOLT , WINTERHAGER ELKE , REGIDOR PEDRO , SCOTTI SIMONE
IPC分类号： G01N33/53 , C12M1/00 , C12N15/09 , C12Q1/68 , C12Q1/6809 , C12Q1/6837 , C12Q1/6883 , G01N33/566 , G01N33/68 , G01N37/00
摘要： PROBLEM TO BE SOLVED: To provide a new means for diagnosing heterotopic endometriosis. SOLUTION: This means for diagnosing the heterotopic endometriosis in vitro is characterized by measuring the amount of at least one genetic product selected from the group consisting of fibronectin, insulin-like proliferation factor- bound protein-2, membrane-penetrating receptor PTK7, platelet-originated proliferation factor receptor alpha, collagen XVIII type alpha 1, subtilisin-like protein (PACE 4), laminin M chain (merosin), elastin, IV type collagen alpha 2, p27 interferon alpha-derived gene, reticulocalbin, aldehyde dehydrogenase 6, gravin, nidogen, and phospholipase C epsilon in a patient sample, comparing the measured amount with the amount of the genetic product in a control sample, and allowing to suggest the presence of the heterotopic endometriosis by showing that the amount of the genetic product in the patient sample is less than the amount of the genetic product in the control sample.

7. 发明专利

NO20015821A 未知
公开(公告)号：NO20015821A
公开(公告)日：2002-05-31
申请号：NO20015821
申请日：2001-11-29
申请人： SCHERING AG
发明人： AHRENS-FATH ISABELLE , HAENDLER BERNARD
IPC分类号： G01N33/50 , A61K31/711 , A61K45/00 , A61K48/00 , A61P15/16 , A61P35/00 , C07K7/06 , C07K14/72 , C07K16/28 , C12N5/10 , C12N15/09 , C12N15/12 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566 , G01N33/574 , G01N33/74 , C12N1/21 , C12N15/63
CPC分类号： G01N33/57434 , A61K48/00 , C07K14/721 , C07K16/2869 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/743 , G01N2800/52

8. 发明专利

HUT76972A PROCESS FOR MANUFACTURE OF A MODIFIED COLLAGEN-INDUCED PLATELET AGGREGATION INHIBITOR PALLIDIPIN 未知
公开(公告)号：HUT76972A
公开(公告)日：1998-01-28
申请号：HU9701823
申请日：1995-09-11
申请人： SCHERING AG
发明人： BECKER ANDREAS , HAENDLER BERNARD , NOESKE-JUNGBLUT CHRISTIANE
IPC分类号： C12N15/09 , A61K38/00 , A61K38/17 , A61P7/02 , A61P9/10 , A61P35/00 , C07K14/435 , C12N1/21 , C12N15/12 , C12N15/30 , C12N15/62 , C12P21/00 , C12P21/02 , C12R1/19
摘要： PCT No. PCT/EP95/03573 Sec. 371 Date Jun. 16, 1997 Sec. 102(e) Date Jun. 16, 1997 PCT Filed Sep. 11, 1995 PCT Pub. No. WO96/08563 PCT Pub. Date Mar. 21, 1996The invention provides a process of manufacture of a recombinant protein called Asp-Pallidipin. Asp-Pallidipin inhibits the collagen-induced platelet aggregation of mammalian platelets. The Asp-Pallidipin comprises (i) a protein (Pallidipin) selected from the group of Pallidipin proteins, and (ii) the amino acid aspartic acid, wherein the aspartic acid is connected by a peptide bond with the N-terminal end of Pallidipin. The process comprises the steps aa) transfecting at least one bacterium with an appropriate vector, wherein the vector comprises: (i) a DNA or cDNA coding for the recombinant Asp-Pallidipin (ii) a suitable signal peptide sequence which signal sequence is cleaved so that the amino acid aspartic acid is in the position +1 of the amino acid sequence seen from the position of the Pallidipin and (iii) a suitable promoter; bb) expressing the preprotein comprising Asp-Pallidipin and the signal sequence; cc) transporting the Asp-Pallidipin from the cytoplasm of the bacterium to the periplasm, cleavage of the preprotein by at least one protease during the transport, producing the Asp-Pallidipin, dd) isolating the Asp-Pallidipin by extracting the periplasm, and ee) purifying the Asp-Pallidipin. The protein is used as a medicament for inhibiting of collagen-induced human platelet aggregation or of cancer with metastatic tumor cells.

9. 发明专利

FI971013A0 未知
公开(公告)号：FI971013A0
公开(公告)日：1997-03-11
申请号：FI971013
申请日：1997-03-11
申请人： SCHERING AG
发明人： NOESKE-JUNGBLUT CHRISTIANE , BECKER ANDREAS , HAENDLER BERNARD
IPC分类号： C12N15/09 , A61K38/00 , A61K38/17 , A61P7/02 , A61P9/10 , A61P35/00 , C07K14/435 , C12N1/21 , C12N15/12 , C12N15/30 , C12N15/62 , C12P21/00 , C12P21/02 , C12R1/19 , C12N
摘要： PCT No. PCT/EP95/03573 Sec. 371 Date Jun. 16, 1997 Sec. 102(e) Date Jun. 16, 1997 PCT Filed Sep. 11, 1995 PCT Pub. No. WO96/08563 PCT Pub. Date Mar. 21, 1996The invention provides a process of manufacture of a recombinant protein called Asp-Pallidipin. Asp-Pallidipin inhibits the collagen-induced platelet aggregation of mammalian platelets. The Asp-Pallidipin comprises (i) a protein (Pallidipin) selected from the group of Pallidipin proteins, and (ii) the amino acid aspartic acid, wherein the aspartic acid is connected by a peptide bond with the N-terminal end of Pallidipin. The process comprises the steps aa) transfecting at least one bacterium with an appropriate vector, wherein the vector comprises: (i) a DNA or cDNA coding for the recombinant Asp-Pallidipin (ii) a suitable signal peptide sequence which signal sequence is cleaved so that the amino acid aspartic acid is in the position +1 of the amino acid sequence seen from the position of the Pallidipin and (iii) a suitable promoter; bb) expressing the preprotein comprising Asp-Pallidipin and the signal sequence; cc) transporting the Asp-Pallidipin from the cytoplasm of the bacterium to the periplasm, cleavage of the preprotein by at least one protease during the transport, producing the Asp-Pallidipin, dd) isolating the Asp-Pallidipin by extracting the periplasm, and ee) purifying the Asp-Pallidipin. The protein is used as a medicament for inhibiting of collagen-induced human platelet aggregation or of cancer with metastatic tumor cells.

10. 发明专利

DE10048633A1 未知
公开(公告)号：DE10048633A1
公开(公告)日：2002-04-18
申请号：DE10048633
申请日：2000-09-25
申请人： SCHERING AG
发明人： HES-STUMPP HOLGER , HAENDLER BERNARD , KRAETZSCHMAR JOERN , KREFT BERTHOLD , WINTERHAGER ELKE , REGIDOR PEDRO , SCOTTI SIMONE
IPC分类号： G01N33/53 , C12M1/00 , C12N15/09 , C12Q1/68 , C12Q1/6809 , C12Q1/6837 , C12Q1/6883 , G01N33/566 , G01N33/68 , G01N37/00 , C07H21/00 , G01N33/577

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式